Chiesi Italia in the news

Chiesi and Bending Spoons are the only two Italian companies listed in the top 100 best European workplaces, ranking 21st and 69th respectively.

Hilton leads the 2026 Fortune 100 Best Companies to Work For in Europe list, with Chiesi and Bending Spoons being the only two Italian companies included.

Chiesi (21st) and Bending Spoons (69th) are the only two Italian companies in the top 100 best workplaces in Europe, highlighting the importance of trust in the workplace for business success and employee retention.

Chiesi is actively implementing sustainable mobility strategies, including electrifying its vehicle fleet and promoting eco-friendly commuting options for employees, to achieve its Net Zero 2035 target.

Chiesi Group is transforming its historical industrial site in Parma into 'Chiesi Gardens,' a mixed-use urban space with offices, an innovation hub, and public areas, set to open in 2029.

Chiesi Group has appointed David Khougazian as its new CEO, effective October 15, 2026, to drive innovation and sustainable growth.

Chiesi Italia is advancing towards introducing lower carbon footprint inhalers in Europe, with regulatory validation for new propellant-based respiratory therapies.

Chiesi Italia is developing low-carbon inhalers with a new propellant, securing European regulatory validation for new therapeutic applications.

Chiesi is redeveloping its former pharmaceutical plant in Parma into 'Chiesi Gardens', a mixed-use urban space with public gardens, innovation hubs, and community facilities.

Chiesi's Clenil Modulite inhalers, using the new HFA-152a propellant, received MHRA approval, marking a significant step towards their Net Zero goal.

Chiesi published its 2025 Sustainability Report, detailing record investments in R&D, continuous B Corp certification, significant decarbonization efforts, and strong social engagement.

Chiesi's 2025 Sustainability Report highlights a record 885 million euro investment in R&D, its B Corp re-certification, and significant progress towards ambitious net-zero environmental targets.

Chiesi invested a record 885 million euros, or nearly a quarter of its revenue, into research and development, solidifying its position as a leading innovator in the biopharmaceutical sector.

Chiesi Farmaceutici received a top innovation award for developing a patient-specific digital twin of the respiratory system to improve drug delivery and R&D efficiency.

Chiesi Italia's Senior Director of Communication stated the pharmaceutical industry has an ethical and social responsibility to improve the environment and society while offering therapeutic options.

Chiesi Italia's CEO, Raffaello Innocenti, calls for Italy to adopt international standards like PAS 2090:2025 to homogenize regulations, enabling assessment of pharmaceutical products' environmental impact and incentivizing sustainable options.

Chiesi Italia advocates for corporate social responsibility and environmental sustainability to improve respiratory health outcomes.

Chiesi Italia's CEO advocates for standardized environmental impact assessments and rewards for sustainable pharmaceutical products in Italy.

Chiesi Italia is integrating environmental and social goals into its strategic framework for respiratory therapy development.

Chiesi Italia calls for stable regulations to integrate environmental sustainability with innovative respiratory care and industrial growth.